Beat Penny Stocks

RATED A "STRONG BUY" WITH A TINY FLOAT, NDTP COULD BE THE NEXT OTC PHARMA PLAY TO GO PARABOLIC!

logo
NDT PHARMACEUTICALS INC.

US PINK SYMBOL: NDTP
Last Price: 1.40 | Website | SEC Filings | Latest News

Good Morning Subscriber,

Fire up those trading screens because this unique Pharma play dropped HUGE news yesterday and is starting to pick up steam!

With a super LOW FLOAT, this penny play started lighting up screens due to a recent acquisition in the Wellness space & just yesterday annouced of a MAJOR Government contract.

This puts Today's Alert in the midst of a $6.8 TRILLION global wellness industry market, projected to grow to $7.4 trillion in 2025 and an anticipated rise to $9.8 trillion by 2029!

So traders, without further ado let's dig in.

WE ARE ISSUING AN IMMEDIATE ALERT ON NDTP TODAY!

NDT Pharmaceuticals, Inc. (OTC: NDTP) is a publicly traded company focused on advancing innovative consumer health and wellness solutions.

With its recent acquisition of Good Salt Life Inc., NDTP has expanded its strategic direction into sustainable, science-driven products that promote healthier living. The Company is committed to building value through investments in brands that protect people, pets, and the planet while aligning with growing consumer demand for eco-friendly and health-conscious alternatives.

Look at the news NDTP just announced: Good Salt(TM) Life, Secures Major Government Contract, Deploying Advanced Biosafety Ecosystem in Tennessee State Prisons

So what's the hype on NDTP's Good Salt Life Inc?

Good Salt Life Inc. is a unique biosafety and sanitation tech company using HOCl (hypochlorous acid) — a compound used in hospitals, emergency medicine, and high-grade cleaning environments.

But here’s the key:

🔥 NDTP's GOOD SALT LIFE™ is NOT just selling “cleaning products.”

They are developing EPA-registered, hospital-tested, medical-grade biosafety systems — AND selling consumer versions via huge retail channels.

This includes: Amazon, Walmart, Chewy, Retail & hospitality partners, Cruise lines, Hospitals, Clinics, Senior living centers, Luxury hotels, and Pet-care facilities.

And the crown jewel:

👉 Their ByoCart™ Disinfection System has already been deployed in healthcare environments — including Baptist Hospital.

Not to mention, NDTP is EXPANDING their offering with NORWEGIAN CRUISE LINES!

This is SERIOUS validation.
This is REAL deployment.
This is an ACTUAL operational subsidiary — NOT a “concept.

Here’s what NDTP is rolling out:

🧪 HOCl antimicrobial technology — clinically backed, non-toxic
🚼 Baby-safe & pet-safe cleaning line
🚢 Cruise & hospitality biosafety systems
🏥 Hospital-grade air purification & surface systems
🐶 Pet wellness sanitization products
🏬 Retail-ready SKU lineup for large chains
🧰 ByoCart™ mobile disinfection system

On October 9th, the company submitted a "me-too" registration application to the U.S. Environmental Protection Agency (EPA) for its hypochlorous acid (HOCl) disinfectant, which, if approved, would expand the label to include an efficacy claim for Clostridioides difficile (C. diff) on its label.

"We are extremely excited about this important milestone and are eagerly awaiting the EPA's decision, and if approval is granted, it will represent a major milestone," said Bill Spilfogel, Senior Vice President of Regulatory Affairs and spokesperson for Good Salt Life.

"Approval of a C. diff efficacy claim would represent a groundbreaking advancement for Good Salt Life, solidifying our mission to enhance biosecurity in critical environments."

NDTP is NOT just another OTC biotech claiming the world. NDTP has a real operating subsidiary with distribution already underway.

Here’s what the chart is telling us:

📈 Price peeking out past long-term trendlines
📈 Resistance thinning
📈 Support forming under recent price action
📈 Tightening = pre-breakout coil

We’ve seen this pattern countless times:

When low-float OTC stocks coil quietly… the move is rarely quiet.

And with NDTP’s recent chart Breakout & TINY Float of just 16.9 MIL shares a/o 8/16/2025, ANY continuation of this momentum could create a MAJOR MOVE.

Not to mention, Investing.com has now given NDTP it's highest rating of "STRONG BUY"

THE BOTTOM LINE
For an OTC Penny Stock in the Pharma/Wellness Sector, NDTP absolutely checks every box...

🔥 A GROWING operating subsidiary (Good Salt Life™)
🔥 Targeting a massive global market
🔥 Distribution in big-box retail ecosystems
🔥 HOCl tech = trending in both medical and consumer health
🔥 Low float
🔥 OTC = explosive potential on volume surges

If retailers add more SKUs…
If Good Salt expands its commercial rollouts…
If a new hospital validates ByoCart…
If Amazon sales spike…

NDTP is EXACTLY the kind of low-float speculative play that can explode with the right catalyst at the right time.

AND WALL STREET IS BARELY WATCHING NDTP… YET!

No analysts.
No glowing research notes.
No mainstream fund ownership.
No CNBC segments.

Talk about an Under-the-Radar play? This is EXACTLY how major low-float runs start.

REMEMBER WHERE YOU HEARD OF NDTP FIRST!

Make sure you put it on your screen AT THE OPENING BELL!

Good Trading,

BEATPENNYSTOCKS.COM

Still need an Online Broker to place trades?
RobinHood & WeBull do not let you trade Penny Stocks!

Our Team HIGHLY recommends ETRADE!

Advertisement -

Disclaimer – This newsletter is owned, operated, and edited by Stellar Media Group, LLC. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. Conduct your own research. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “Stellar Media” refers to Stellar Media Group, LLC. Our business model is to be financially compensated to market and promote small public companies. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. We do NOT own any shares in NDTP. We has been compensated ten thousand dollars cash via bank wire by a third party, Link Media LLC via Shore Thing Media, LLC for this NDT Pharmaceuticals, Inc. marketing services contract. Stellar Media’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Stellar Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.